What You Should Know
- Forus, the AI-powered network connecting physicians, retail and specialty pharmacies, commercial payers, and biopharma manufacturers, announced a $150M Series C financing round at a $3B valuation.
- The round triples the company’s valuation just months following its Series B round, lifting cumulative equity financing past $300M.
- Led by seed-stage backer Bain Capital Ventures, the insider round featured 100% reinvestment from existing institutional backers, including Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Avra, Human Capital, Neo, Vast Ventures, and SV Angel.
- Directly targets a core breakdown in specialty medicine: one in three patients prescribed therapies for high-cost or complex conditions never receives their initial dose, while those who do regularly wait weeks or months due to prior authorization (PA) and financial clearance hurdles.
Assigning an AI Agent to Every Prescription
Founded in 2023 by Sahir Jaggi, Forus provides a platform that functions as an intelligent connective tissue linking prescribing physicians, specialty pharmacies, payers, and biopharma commercial teams. Offered free to providers and patients, the platform gives every qualifying prescription a dedicated, autonomous AI agent embedded directly into clinical electronic workflows.
Operating like an automated case manager, each agent reasons across a patient’s medical records, insurance coverage rules, and financial assistance options to orchestrate the fulfillment path:
- Accelerated Prior Authorization: By cross-referencing clinical indications with dynamic payer policies, approval times shrink from several weeks to under 48 hours.
- Financial Assistance & Hub Automation: Connects eligible patients with manufacturer copay cards, foundation grants, and zero-dollar access programs in real time.
- Specialty Pharmacy Orchestration: Routes scripts directly to network-approved dispensing pharmacies with verified stock, enabling patients to start complex therapies within one to two weeks rather than months.
Rapid Specialty Adoption and National Footprint
The platform has established a widespread national presence, with healthcare providers across all 50 U.S. states using Forus to treat patients residing in 85% of U.S. residential ZIP codes.
In its initial rollout specialty of rheumatology, more than one-third of all U.S. providers have adopted the network, with double-digit provider adoption scaling across several follow-on specialties.
Beyond provider workflow relief, the network generates actionable visibility across the pharmaceutical lifecycle. By capturing where prescriptions stall and how therapies perform in real-world settings, Forus now collaborates with 9 of the top 15 global biopharma companies to streamline commercial product launches and optimize clinical trial protocol design.
“We are putting the Forus platform in every doctor’s office in the country, so every disease is treated with the best medicine science can offer,” said Sahir Jaggi, CEO and founder of Forus. “Medicine is advancing faster than at any point in history, increasing the urgency to make sure those advances reach the people they’re meant for. We are building Forus to ensure science is the only limit to medicine.”
